New biomarkers in non-Hodgkin lymphoma and acute leukemias

Benjamín Rubio-Jurado, Lluvia Sugey Sosa-Quintero, Ivette Lenina Carrasco-Martinez, Armando Norato-Delgado, Eduardo García Luna Martínez, Sandra Guzmán-Silahua, Carlos Riebeling-Navarro, Arnulfo Hernan Nava-Zavala

Resultado de la investigación


Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.

Idioma originalEnglish
Título de la publicación alojadaAdvances in Clinical Chemistry
EditoresGregory S. Makowski
EditorialAcademic Press Inc.
Número de páginas35
ISBN (versión impresa)9780128211663
EstadoPublished - 2020

Serie de la publicación

NombreAdvances in Clinical Chemistry
ISSN (versión impresa)0065-2423
ISSN (versión digital)2162-9471

Nota bibliográfica

Publisher Copyright:
© 2020 Elsevier Inc.

All Science Journal Classification (ASJC) codes

  • Química (todo)
  • Bioquímica clínica


Profundice en los temas de investigación de 'New biomarkers in non-Hodgkin lymphoma and acute leukemias'. En conjunto forman una huella única.

Citar esto